NASDAQ:ELOX

Eloxx Pharmaceuticals - ELOX Stock Forecast, Price & News

$2.91

+0.10 (+3.56%)

(As of 12/9/2022 02:16 PM ET)

Add

Compare

Today's Range: $2.80
▼
$2.91
50-Day Range: $0.10
▼
$4.13
52-Week Range: $2.74
▼
$40.40

Volume: 47 shs
Average Volume: 22,308 shs
Market Capitalization: $6.31 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $2.38

Eloxx Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 15.8% Downside
$2.38 Price Target
Short Interest: Healthy
0.87% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($18.80) to ($19.20) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.40 out of 5 stars

1.5

Analyst's Opinion

Consensus Rating
Eloxx Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $2.38, Eloxx Pharmaceuticals has a forecasted downside of 15.8% from its current price of $2.82.
Amount of Analyst Coverage
Eloxx Pharmaceuticals has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.87% of the float of Eloxx Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Eloxx Pharmaceuticals has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Eloxx Pharmaceuticals has recently increased by 13.02%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Eloxx Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Eloxx Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ELOX.

3.0

News and Social Media Coverage

News Sentiment
Eloxx Pharmaceuticals has a news sentiment score of 1.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.
Search Interest
Only 1 people have searched for ELOX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
1 people have added Eloxx Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Eloxx Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
18.60% of the stock of Eloxx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 15.01% of the stock of Eloxx Pharmaceuticals is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Eloxx Pharmaceuticals are expected to decrease in the coming year, from ($18.80) to ($19.20) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Eloxx Pharmaceuticals is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Eloxx Pharmaceuticals is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Eloxx Pharmaceuticals has a P/B Ratio of 0.27. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Eloxx Pharmaceuticals (NASDAQ:ELOX) Stock

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.

Receive ELOX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eloxx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ELOX Stock News Headlines

December 1, 2022 | finance.yahoo.com

Eloxx Pharmaceuticals Announces Reverse Stock Split Effective

November 10, 2022 | finance.yahoo.com

Eloxx Pharmaceuticals Reports Third Quarter 2022 Financial and Operating Results and Provides Business Update

November 1, 2022 | finance.yahoo.com

Eloxx Pharmaceuticals Announces Opening of Clinical Trial Sites for Phase 2 Study of ELX-02 for the Treatment of Alport Syndrome

October 19, 2022 | forbes.com

Eloxx Pharmaceuticals

October 12, 2022 | finanznachrichten.de

DelveInsight Business Research, LLP: Cystic Fibrosis Market to Showcase Growth at a CAGR of 9% During the Forecast Period (2022-2032) | DelveInsight

September 17, 2022 | seekingalpha.com

ELOX Eloxx Pharmaceuticals, Inc.

September 16, 2022 | finance.yahoo.com

Eloxx (ELOX) Down After Cystic Fibrosis Study Fails to Meet Goal

September 15, 2022 | in.investing.com

After-Hours Movers: Danaher Jumps on Spinoff Plans, Arconic Sinks on Lower Outlook

September 15, 2022 | nasdaq.com

Eloxx Pharma Shares Plummet As Class 1 Cystic Fibrosis Trial Fails

September 14, 2022 | msn.com

Eloxx Shares Plummet As Mid-Stage Cystic Fibrosis Study Results Miss Efficacy Endpoints

September 14, 2022 | finance.yahoo.com

Eloxx Pharmaceuticals Reports Topline Results from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients

August 16, 2022 | investing.com

Eloxx Pharmaceuticals Misses Q2 EPS by 2c

August 16, 2022 | seekingalpha.com

Eloxx Pharmaceuticals GAAP EPS of -$0.12 in-line

August 15, 2022 | finance.yahoo.com

Eloxx Pharmaceuticals Reports Second Quarter 2022 Financial and Operating Results and Provides Business Update

July 5, 2022 | finance.yahoo.com

Eloxx Pharmaceuticals Announces Changes to Board of Directors

May 10, 2022 | seekingalpha.com

Eloxx Pharmaceuticals GAAP EPS of $0.13 beats by $0.24

May 10, 2022 | finance.yahoo.com

Eloxx Pharmaceuticals Reports First Quarter 2022 Financial and Operating Results and Provides Business Update

March 31, 2022 | uk.investing.com

Eloxx to Test Its Lead Product Candidate, ELX-02, In Rare Kidney Disease

March 31, 2022 | seekingalpha.com

Eloxx Pharmaceuticals GAAP EPS of -$0.14 misses by $0.02

March 31, 2022 | finance.yahoo.com

Eloxx Pharmaceuticals Reports Fourth Quarter 2021 Financial and Operating Results and Provides Business Update

March 30, 2022 | morningstar.com

Eloxx Pharmaceuticals Announces Therapeutic Development Award from Cystic Fibrosis Foundation | Morningstar

March 30, 2022 | seekingalpha.com

Eloxx Pharma to target Alport syndrome with lead candidate

March 29, 2022 | finance.yahoo.com

CF Foundation Funds Expansion of Clinical Trial Program for Potential Nonsense Mutations Therapy

March 29, 2022 | finance.yahoo.com

Eloxx Pharmaceuticals Announces Therapeutic Development Award from Cystic Fibrosis Foundation

January 15, 2022 | nasdaq.com

Eloxx Pharmaceuticals Inc Shares Fall 5.6% Below Previous 52-Week Low - Market Mover

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ELOX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eloxx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ELOX Company Calendar

Last Earnings: 11/10/2022
Today: 12/09/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 3/30/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ELOX
CUSIP: N/A
CIK: 1035354
Web: www.eloxxpharma.com
Phone: (781) 577-5300
Fax: 908-864-4440
Employees: 25
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $2.38
High Stock Price Forecast: $4.00
Low Stock Price Forecast: $1.00
Forecasted Upside/Downside: -18.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($19.20)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-66,730,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -541.57%
Return on Assets: -112.63%

Debt

Debt-to-Equity Ratio: 6.14
Current Ratio: 1.18
Quick Ratio: 1.18

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $10.38 per share
Price / Book: 0.28

Miscellaneous

Outstanding Shares: 2,170,000
Free Float: 1,763,000
Market Cap: $6.31 million
Optionable: Optionable
Beta: 2.06

Key Executives

Mr. Sumit Aggarwal M.B.A. (Age 49)
Pres, CEO & Director
Comp: $874.7k

Mr. Daniel E. Geffken M.B.A. (Age 65)
MBA, Interim CFO, Principal Financial Officer & Principal Accounting Officer
Comp: $130.75k

Dr. Vijay Modur MBBS (Age 54)
Ph.D., Head of R&D
Comp: $648.29k

Ms. Barbara Ryan
Investor Relations Officer

Dr. Ali Hariri M.D.
Chief Medical Officer

Mr. Matthew Goddeeris Ph.D.
VP of Research

Key Competitors

View All Competitors

Insiders & Institutions

Vanguard Group Inc.
Sold 117,680 shares on 11/15/2022
Ownership: 3.121%

View All Insider Transactions
View All Institutional Transactions

ELOX Stock - Frequently Asked Questions

Should I buy or sell Eloxx Pharmaceuticals stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eloxx Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ELOX shares.
View ELOX analyst ratings or view top-rated stocks.
What is Eloxx Pharmaceuticals' stock price forecast for 2023?: 2 Wall Street research analysts have issued 1-year target prices for Eloxx Pharmaceuticals' shares. Their ELOX share price forecasts range from $1.00 to $4.00. On average, they predict the company's share price to reach $2.38 in the next twelve months. This suggests that the stock has a possible downside of 15.5%.
View analysts price targets for ELOX or view top-rated stocks among Wall Street analysts.
How have ELOX shares performed in 2022?: Eloxx Pharmaceuticals' stock was trading at $0.7062 at the start of the year. Since then, ELOX shares have increased by 297.9% and is now trading at $2.81.
View the best growth stocks for 2022 here.
When is Eloxx Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our ELOX earnings forecast.
How were Eloxx Pharmaceuticals' earnings last quarter?: Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) announced its quarterly earnings data on Thursday, November, 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.11) by $0.02.

What is Greg Williams' approval rating as Eloxx Pharmaceuticals' CEO?: 1 employees have rated Eloxx Pharmaceuticals Chief Executive Officer Greg Williams on Glassdoor.com. Greg Williams has an approval rating of 49% among the company's employees. This puts Greg Williams in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 48.0% of employees surveyed would recommend working at Eloxx Pharmaceuticals to a friend.
What is Eloxx Pharmaceuticals' stock symbol?: Eloxx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ELOX."
Who are Eloxx Pharmaceuticals' major shareholders?: Eloxx Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.12%). Insiders that own company stock include Daniel E Geffken, Pontifax Management 4 GP (20 and Rajesh B Parekh.
View institutional ownership trends.
How do I buy shares of Eloxx Pharmaceuticals?: Shares of ELOX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Eloxx Pharmaceuticals' stock price today?: One share of ELOX stock can currently be purchased for approximately $2.81.
How much money does Eloxx Pharmaceuticals make?: Eloxx Pharmaceuticals (NASDAQ:ELOX) has a market capitalization of $6.10 million. The company earns $-66,730,000.00 in net income (profit) each year or ($19.20) on an earnings per share basis.
How can I contact Eloxx Pharmaceuticals?: Eloxx Pharmaceuticals' mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The official website for the company is www.eloxxpharma.com. The company can be reached via phone at (781) 577-5300, via email at info@eloxxpharma.com, or via fax at 908-864-4440.

This page (NASDAQ:ELOX) was last updated on 12/9/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial